Bellevue Group’s Pacific Biosciences PACB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-4,592,251
| Closed | -$17.2M | – | 172 |
|
|
2024
Q1 | $17.2M | Sell |
4,592,251
-2,724,877
| -37% | -$10.2M | 0.26% | 81 |
|
|
2023
Q4 | $71.8M | Buy |
7,317,128
+71,940
| +1% | +$706K | 1.1% | 27 |
|
|
2023
Q3 | $60.5M | Sell |
7,245,188
-297,641
| -4% | -$2.49M | 0.97% | 27 |
|
|
2023
Q2 | $100M | Buy |
7,542,829
+516,723
| +7% | +$6.87M | 1.43% | 21 |
|
|
2023
Q1 | $81.4M | Buy |
7,026,106
+547,181
| +8% | +$6.34M | 1.18% | 28 |
|
|
2022
Q4 | $53M | Buy |
6,478,925
+1,039,374
| +19% | +$8.5M | 0.7% | 45 |
|
|
2022
Q3 | $31.6M | Sell |
5,439,551
-521,678
| -9% | -$3.03M | 0.45% | 62 |
|
|
2022
Q2 | $26.3M | Buy |
5,961,229
+1,079,477
| +22% | +$4.77M | 0.37% | 73 |
|
|
2022
Q1 | $44.4M | Buy |
4,881,752
+3,328,729
| +214% | +$30.3M | 0.52% | 61 |
|
|
2021
Q4 | $31.8M | Sell |
1,553,023
-90,136
| -5% | -$1.84M | 0.33% | 84 |
|
|
2021
Q3 | $42M | Hold |
1,643,159
| – | – | 0.43% | 74 |
|
|
2021
Q2 | $57.5M | Buy |
1,643,159
+25,654
| +2% | +$897K | 0.56% | 61 |
|
|
2021
Q1 | $53.9M | Sell |
1,617,505
-80,674
| -5% | -$2.69M | 0.57% | 57 |
|
|
2020
Q4 | $44.1M | Sell |
1,698,179
-2,206,288
| -57% | -$57.2M | 0.5% | 58 |
|
|
2020
Q3 | $38.5M | Sell |
3,904,467
-4,459,274
| -53% | -$44M | 0.53% | 55 |
|
|
2020
Q2 | $28.9M | Buy |
8,363,741
+984,950
| +13% | +$3.4M | 0.41% | 61 |
|
|
2020
Q1 | $22.6M | Buy |
7,378,791
+1,644,482
| +29% | +$5.03M | 0.44% | 60 |
|
|
2019
Q4 | $29.5M | Buy |
5,734,309
+3,360,522
| +142% | +$17.3M | 0.47% | 52 |
|
|
2019
Q3 | $12.2M | Buy |
+2,373,787
| New | +$12.2M | 0.23% | 78 |
|
|
2018
Q4 | – | Sell |
-2,575,000
| Closed | -$13.9M | – | 141 |
|
|
2018
Q3 | $13.9M | Buy |
+2,575,000
| New | +$13.9M | 0.88% | 40 |
|